

Cynomolgus IL-2RA Protein; hFc Tag

Product Information


Product Name	Cynomolgus IL-2RA Protein; hFc Tag
Storage temp	Store at $\leq -70^{\circ}\text{C}$, stable for 6 months after receipt. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Catalog# / Size	GM-88757RP-100 / 100 μg GM-88757RP-1000 / 1 mg

Protein Information

Alternative Names	CD25, p55, IL2-RA, IL-2-RA
Source	Cynomolgus IL-2RA Protein; hFc Tag (GM-88757RP) is expressed from human 293 cells (HEK-293). It contains AA Glu 22 - Glu 238 (Accession # H6WS54). This protein carries a hFc tag at the C-terminus.
Purity	> 90% as determined by SDS-PAGE
Endotoxin	< 1 EU/ μg , determined by LAL gel clotting assay
Predicted Mol Mass	50.4 kDa
Formulation	Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4.
Description	IL-2RA protein, full name Interleukin-2 Receptor Subunit Alpha, is an important cell surface receptor protein and a member of the interleukin-2 receptor family. IL-2RA protein, also known as CD25, forms the high-affinity heterotrimeric IL-2 receptor complex together with IL-2RB (CD122) and the common gamma chain (IL-2RG, CD132). Abnormal expression of IL-2RA protein is closely associated with the occurrence and development of various malignant tumors and immune-related disorders, including adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL), hairy cell leukemia, and certain solid tumors. In tumor cells and the tumor microenvironment, overexpression of IL-2RA can promote tumor cell survival and proliferation through sustained IL-2 signaling, while elevated soluble IL-2RA (sCD25) levels in patient serum are often correlated with poor prognosis and disease progression in various hematological malignancies. In summary, IL-2RA protein plays a crucial role in immune regulation and tumor immunology. It is of great significance for understanding the mechanisms of immune escape and T-cell dysregulation in cancer, developing novel targeted therapeutic strategies, and evaluating patient prognosis, particularly in the context of hematological malignancies and immune checkpoint-based combination therapies.


Version:4.0

SDS-PAGE



On SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity-ELISA



Cynomolgus IL-2RA Protein; hFc Tag (Catalog # GM-88757RP) was immobilized at 2 μ g/ml (100 μ L/well). Increasing concentrations of Anti-CD25 hIgG1 Antibody (Basiliximab) (Catalog # GM-52329AB) were added.